Patients were required to have CD19-positive ALL, and have disease which was either refractory to induction, refractory to reinduction, in second or greater untreated relapse, relapse following hematopoietic stem cell transplantation (HSCT), or not otherwise being considered for HSCT. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.